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Abstract
Biodistribution and fate of transplanted stem cells via longitudinal monitoring has been successfully achieved in the last decade
using optical imaging. However, sensitive longitudinal imaging of transplanted stem cells in deep tissue like the brain remains
challenging not only due to low light penetration but because of other factors such as low or inferior expression levels of
optical reporters in stem cells and stem cell death after transplantation. Here we describe an optimized imaging protocol for
sensitive long-term monitoring of bone marrow-derived human mesenchymal stem cells (hMSCs) expressing a novel biolu-
minescent/near infrared fluorescent (NIRF) fusion reporter transplanted in mouse brain cortex. Lentivirus expressing the
luc2-iRFP720 reporter, a fusion between luc2 codon-optimized firefly luciferase (luc2) and the gene encoding NIRF protein
iRFP720, was generated to transduce hMSCs. These cells were analyzed for their fluorescent and bioluminescent emission and
checked for their differentiation potential. In vivo experiments were performed by transplanting decreasing amounts of
luc2-iRFP720 expressing hMSCs in mouse brain, followed by fluorescence and bioluminescence imaging (BLI) starting 1 wk
after cell injection when the blood–brain barrier was restored. Bioluminescent images were acquired when signals peaked
and used to compare different luc2 substrate performances, that is, D-luciferin (D-Luc; 25 mM/kg or 943 mM/kg) or CycLuc1
(25 mM/kg). Results showed that luc2-iRFP720 expressing hMSCs maintained a good in vitro differentiation potential toward
adipocytes, chondrocytes, and osteocytes, suggesting that lentiviral transduction did not affect cell behavior. Moreover, in vivo
experiments allowed us to image as low as 1  105 cells using both fluorescence and BLI. The highest bioluminescent signals
(*1 107 photons per second) were achieved 15 min after the injection of D-Luc (943 mM/kg). This allowed us to monitor as
low as 1  105 hMSCs for the subsequent 7 wk without a significant drop in bioluminescent signals, suggesting the sustained
viability of hMSCs transplanted into the cortex.
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Introduction
Stem cell transplantation in the brain holds promise as a
treatment for different neurological disorders such as stroke,
brain injury, Alzheimer’s disease, and other neurodegenera-
tive diseases. In fact, stem cell transplantation has the poten-
tial to restore function when transplanted cells differentiate
and reconstitute neural circuits or when they secrete factors
that support the host cells.1,2 In addition, human mesenchy-
mal stem cells (hMSCs) have created effects by modulating
the immune system3 or as carriers for anticancer therapeutics
because of their tropism for brain tumors.4,5 In particular,
autologous bone marrow-derived hMSCs are currently
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investigated in clinical trials for treatment of brain injury,
cerebral palsy in children, and chronic stroke.6–8
In the preclinical assessment of cell-based therapies,
longitudinal visualization of transplanted stem cells is very
important as well as the evaluation of their viability and fate.
Commonly, direct labeling of cells before transplantation is
employed, using superparamagnetic and/or fluorescent iron
oxide nanoparticles (e.g., SPIO) for subsequent magnetic
resonance imagining or optical imaging.9 Alternatively,
genetic modification of hMSCs using reporter genes for opti-
cal imaging can be applied.10 Optical imaging using gene
reporters has the advantage of being straightforward and
highly reproducible, and it is associated with relatively low
costs compared to nanoparticle tracking. In addition, since
gene reporters are stably expressed in stem cells, they prove
to be adequate for longitudinal monitoring.11
However, sensitive longitudinal imaging of transplanted
stem cells in the brain remains challenging not only because
of low light penetration in deep tissue but because of other
factors such as low or inferior expression levels of optical
reporters in stem cells and stem cell death after transplanta-
tion.12 To date, stem cells can be successfully imaged using
bioluminescence imaging (BLI) for at least 2 wk following
transplantation in the central nervous system.13,14 We have
recently shown firefly luciferase (luc2) as a favorable reporter
for BLI in the brain thanks to its broad emission spectrum and
good kinetics when using D-luciferin (D-Luc) as a substrate.15
Also, enhanced sensitivity of brain imaging has been reported
with synthetic luciferin CycLuc1 as a substrate.16
Besides using BLI, sensitive fluorescence imaging (FLI)
with near infrared fluorescent proteins (NIRFPs) has shown
promise for in vivo (brain) imaging.17–19 Here we describe
an optimized imaging protocol for the sensitive long-term
monitoring of transplanted hMSCs in mouse brain cortex.
Different fusion proteins of luc2 and NIRFPs were designed,
and the effect of the reporter expression on stem cell viabi-
lity and differentiation potentials was evaluated. In addition,
the sensitivity of stem cell imaging in the mouse brain was
assessed in a longitudinal study.
In particular, 3 pending questions were tackled: (1) Are
there differences in imaging sensitivity between BLI and
near infrared FLI in brain imaging? (2) Which imaging pro-
tocol (D-Luc vs. CycLuc1) ensures the highest sensitivity in
the brain? and (3) Is long-term optical monitoring of trans-
duced hMSCs after implantation feasible?
Materials and Methods
Cloning
Plasmids pN1-iRFP720 and pN1-iRFP670 were obtained
from Addgene (Cambridge, MA, USA). The coding
sequences of iRFP720 and iRFP670 were isolated using
restriction enzymes AgeI and NotI and cloned into pTurbo-
Luc plasmid replacing TurboFP635.20 In the constructs, a
linker of 14 amino acids (QSTVPRARDPPVAT) connected
the C-terminal region of the luc2 gene to the N-terminal
region of the iRFP720 or iRFP670 protein resulting in
pluc2-iRFP720 and pluc2-iRFP670, respectively. Next, the
luc2-iRFP720 sequence was cut blunt and cloned into the
multiple cloning site of lentiviral vector pRLPGK21 under
the control of the phosphoglycerate kinase (PGK) promoter.
Cell Culture
Human embryonic kidney (HEK)-293 cells were expanded
in Dulbecco’s modified eagle medium (DMEM; Sigma-
Aldrich, St. Louis, MO, USA) with 10% fetal bovine serum
(FBS; Sigma-Aldrich). The human bone marrow was
collected from anonymous surgical waste material in ortho-
pedic surgery. In agreement with the pertinent Leiden
University Medical Center (LUMC) guidelines, and in
accordance with the Best Practices code of the Dutch
Federation of Biomedical Scientific Societies, and
based on article 467 of the “Wet op de Geneeskundige
Behandelingsovereenkomst,” no informed consent is
required for the use of anonymous and nontraceable biolo-
gical materials, and the institutional ethics committee of the
LUMC waived the need for donor consent. We confirm that
based on the legislation, the institutional ethics committee of
the LUMC waived the need for approval for the use of anon-
ymous surgical waste material. Human mesenchymal stem
cells (hMSCs) were derived from the bone marrow (pas-
sage 2) and expanded in DMEM containing 10% FBS and
1% penicillin/streptomycin (Thermo Fisher Scientific,
Waltham, MA, USA). Basic fibroblast growth factor (bFGF)
(0.5 ng/mL; Sigma-Aldrich) was added to the hMSC expan-
sion medium. hMSCs were seeded (3.75  105 cells per
75 cm2 flask) and incubated at 37 C in 5% CO2 and 95%
O2. Cells were washed with phosphate-buffered saline (PBS)
when 80% confluence was reached and detached with 0.05%
trypsin-ethylenediaminetetraacetic acid (EDTA) (Thermo
Fisher Scientific) for 5 min at 37 C.
Western Blot Analysis
HEK-293 cells (2  106), transfected with pluc2-iRFP720,
pluc2-iRFP670, and pTurboLuc20 plasmids, were lysed
using radioimmunoprecipitation assay buffer (Thermo
Fisher Scientific), and the total protein concentration was
determined utilizing a Pierce bicinchoninic acid (BCA) pro-
tein assay kit (Thermo Fisher Scientific). Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
was performed with 20 mg of cell extract using a 10% SDS
concentration, and proteins were transferred onto a nitrocel-
lulose membrane (GE Healthcare, Chicago, IL, USA).
Immunoblotting was performed after membrane blocking
using rabbit polyclonal luc2 antibody (1:200; Fitzgerald
Industries International, Acton, MA, USA). After overnight
incubation, the membrane was washed and incubated for 1 h
with a secondary mouse anti-rabbit horseradish peroxidase
antibody (1:1,000; Fitzgerald Industries International).
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Pierce enhanced chemiluminescence substrate (Thermo
Fisher Scientific) was utilized for signal detection of the
membrane in the Bio-Rad gel doc apparatus (Bio-Rad
Laboratories, Hercules, CA, USA).
Immunofluorescence for Detection of Fusion Proteins
in HEK-293 Cells
Transfected HEK-293 cells were cultured on 8-well glass
chamber slides (Thermo Fisher Scientific) and transfected
with pluc2-iRFP720, pluc2-iRFP670, and pTurboLuc using
Fugene HD (Promega, Madison, MA, USA). After 24 h,
HEK-293 cells were fixed using 4% formaldehyde. Rabbit
polyclonal luc2 antibody (1:100) and anti-rabbit immuno-
globulin G (IgG) Alexa Fluor 488 secondary antibody
(1:200; Thermo Fisher Scientific) were used for immuno-
fluorescent staining.
Lentiviral Production and Cell Transduction
Third-generation self-inactivating lentiviral particles were
produced using standard protocols as earlier described.21
Lentivirus was titrated using a p24 enzyme-linked immuno-
sorbent assay (Cell Biolabs, San Diego, CA, USA). hMSCs
were cultured in 6-well plates (7.5  104 cells/well) and
transduced with a multiplicity of infection of 10 and the use
of polybrene (8 mg/mL; Sigma-Aldrich). The next day
medium containing the virus was removed, and cells were
passaged twice before selection using fluorescent-activated
cell sorting (FACS). The 633 nm laser was employed for
detection of the iRFP720 protein.
Proliferation of hMSCs
Non transduced hMSCs at passage 3 were seeded at a density
of 8  103 cells/cm2. The day after, cells were transduced
with lentivirus using the protocol described above. Cell via-
bility was assessed after 7 d, by determining the viable/dead
ratio with the trypan blue (0.4%) exclusion assay (Thermo
Fisher Scientific). The number of viable, labeled cells was
calculated in relation to the number of viable, unlabeled cells
(processed the same way). The number of viable cells was
counted for 3 passages after transduction. In addition, white-
field microscopic images were taken 6 d after transduction.
Differentiation and Analysis of hMSCs
Differentiation medium was made with the supplements
and protocol provided by the Mesenchymal Stem Cell Iden-
tification Kit (R&D Systems, Minneapolis, MN, USA). For
all differentiation experiments, expansion medium was
added the day after seeding in the wells and the 15 mL
tubes were replaced with differentiation medium to induce
differentiation. Medium was changed every 2 to 3 d. After
10 to 14 d, differentiation was terminated, and cells were
fixed with 4% formaldehyde. Primary antibodies were
included in the Mesenchymal Stem cell Identification Kit
(R&D Systems).
Adipogenic differentiation. Non transduced hMSCs and trans-
duced hMSCs (hMSC luc2-iRFP720) were seeded in a 6-
well plates or 24-well plates with a density of 3.2 104 cells/
cm2. Rosiglitazone (Sigma-Aldrich) with a final concentra-
tion of 10 mM was added to the adipogenic differentiation
medium. Non transduced hMSCs and luc2-iRFP720 expres-
sing hMSCs were permeabilized and blocked using a solu-
tion of 0.3% Triton X-100 (Sigma-Aldrich), bovine serum
albumin (BSA) (Sigma-Aldrich), and 1% and 10% normal
horse serum (Thermo Fisher Scientific) in PBS. Subse-
quently, cells were immunostained with anti-monoclonal
fatty acid–binding protein (anti-4FABP4; 10 mg/mL), dis-
solved in the same solution (overnight at 4 C). After wash-
ing, donkey polyclonal secondary goat IgG Alexa Fluor 647
antibody (1:200; Thermo Fisher Scientific) was incubated in
the dark for 1 h at room temperature. Staining of nuclei was
performed using 40,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich). Cells were visualized with the Leica TCS
SP8 confocal microscope (Leica Microsystems, Wetzlar,
Germany). For histological stainings, hMSC luc2-iRFP720
was cultured in 6-well plates. Adipogenic-differentiated
cells were incubated for 10 min at room temperature with
filtered 0.3% Oil Red O solution (Sigma-Aldrich).
Osteogenic differentiation. To assess the differentiation poten-
tial of both non transduced hMSCs and transduced hMSCs
(hMSC luc2-iRFP720), cells were seeded in a 6-well plate
with a density of 1.6  104 cells/cm2. Non transduced
hMSCs and luc2-iRFP720 expressing hMSCs were immu-
nostained with a mouse antihuman osteocalcin primary
antibody. Fixed osteogenically differentiated hMSCs were
incubated in the dark for 1 h at room temperature with a
donkey anti-mouse IgG Alexa Fluor 488 secondary anti-
body (1:200; Thermo Fisher). Osteogenic-differentiated
cells were stained with filtered 2% Alizarin Red S solution
(pH ¼ 4.1 to 4.3; Sigma-Aldrich). Cells were visualized
with the Leica TCS SP8 confocal microscope (Leica
Microsystems).
Chondrogenic differentiation. Both non transduced hMSCs and
transduced hMSCs (hMSC luc2-iRFP720) were seeded in a
24-well plate with a density of 5.6  104 cells/cm2. Alter-
natively, 2.5  105 cells in 1 mL expansion medium were
cultured in 15 mL tubes and centrifuged at 200 g for 5 min to
achieve pellet formation. Non transduced hMSCs and luc2-
iRFP720 expressing hMSCs were immunostained with a
goat antihuman aggrecan primary antibody following the
protocol described above. Chondrogenic differentiated cells
cultured in pellets were incubated for 10 to 20 min at room
temperature with filtered 0.4% toluidine blue (Sigma-
Aldrich) dissolved in sodium acetate buffer (sodium acetate
and acetic acid from Sigma-Aldrich; pH ¼ 3.7). For every
staining, a negative control of nondifferentiated hMSCs was
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included. A light microscope with camera was utilized to
observe the staining (Leica DM3000, Leica Microsystems).
Alkaline Phosphatase (ALP) Measurements
Medium samples were taken 14 d after differentiation.
ALP activity was measured by adding 120 nM
p-nitrophenylphosphate (Thermo Fisher Scientific) in
100 mM glycine/1 mM MgCl2/0.1 mM ZnCl2 buffer
(pH ¼ 10.5; Sigma-Aldrich) and measured for 10 min using
a VERSAmax Tunable Microplate Reader at 405 nm (Mole-
cular Devices, Sunnyvale, CA, USA). ALP activity was
determined as the slope of the kinetic measurement (mOD
[optical density]/min) and corrected for number of cells.
Relative Oil Red O Accumulation by
Spectrophotometry
After fixation, cells were rinsed once with PBS, stained with
theOilRedOworking solution for 15min at roomtemperature,
and thenwashed3 times inwater.Thedyewas elutedbyadding
isopropanol.Cellswereplaced ina plate shaker for 15min.One
hundred microliter medium per well was removed and trans-
ferred to a clean 96-well plate for reading the absorbance (OD)
using a VERSAmax Tunable Microplate Reader at 540 nm.
The average absorbances of the blankwells and the control and
test wells were calculated.
In Vitro Imaging of hMSCs
A serial dilution of luc2-iRFP720 expressing hMSCs rang-
ing from 1 105 cells to 3 103 was seeded in triplicate into
a 96-well black plate with clear bottom and imaged first
using an Odyssey scanner (LICOR Biosciences, Lincoln,
NE, USA) at 700 nM to detect fluorescence signals. Then
D-Luc (Promega, Madison, WI, USA) at a final concentra-
tion of 1 mM was added to the wells and imaged 5 min later
using an IVIS Spectrum (Perkin Elmer, Waltham, MA,
USA). The following settings were used: open filter, field
of view (FOV) C, medium binning, and 30-s acquisition.
In Vivo Imaging Experiments
Animal experiments were reviewed and approved by the
Bioethics Committee of Leiden University, the Netherlands.
Eight-wk-old CD-1 nude mice were used for experiments. For
initial assessment of fluorescent protein sensitivity, 1  106
HEK-293 cells transfected with pTurboLuc, pluc2-iRFP720,
and pluc2-iRFP670 were injected subcutaneously. Fluores-
cence signals were measured using an IVIS Spectrum by the
following filter settings (TurboLuc ex/em 570/640 nm,
luc2-iRFP670 ex/em 640/680 nm, and luc2-iRFP720 ex/em
710/760 nm). Then, different amounts of hMSCs (1  106,
1  105, 1  104, and 1  103 cells) were implanted into the
cortex of the mouse to check optical imaging sensitivity using
the novel fusion reporter. In brief, mice were anesthetized
using isofluorane (Piramal Critical, Bethlehem, PA, USA) and
placed in a robot stereotactic device (Neurostar, Tubingen,
Germany). Mouse skulls were drilled using this system, and
cells were injected at a volume of 2 mL into the cortex at 1 mm
depth (Bregma coordinates: AP þ0.5; L + 2.0; DV 1.0).
The subsequent day, a dose of 25 mM/kg of D-Luc was
injected intraperitoneally (i.p.) 15 min prior to imaging at the
IVIS Spectrum imager (Perkin Elmer, Waltham, MA, USA)
using an open filter setting and 30-s acquisition time. iRFP720
fluorescent protein emission was measured using the Pearl
Imaging system (LICOR Biosciences) at the 700 nm setting.
In another set of experiments, 1  105 luc2-iRFP720 expres-
sing hMSCs were implanted at 1 mm depth in the cortex, and
performances of different luciferin substrates were evaluated,
which were 25 mM/kg and 943 mM/kg of D-Luc potassium
salt (Promega) and 25 mM/kg of CycLuc1 (Aobious, Glouce-
ster, MA, USA). Substrates were then injected (i.p.) before
imaging, and signals were collected when emission peaked.
Cells were followed for the subsequent 7 wk using the
imaging protocol determined from previous experiments.
Statistics
Statistical analyses for the experiments (hMSC dilution
series for BLI and FLI (Fig. 5), different doses of D-luc and
CycLuc1 (Fig. 6), and longitudinal optical monitoring of
transplanted hMSCs) were performed using a 1-way analysis
of variance with multiple comparisons using Tukey’s post
hoc test. Data were analyzed using GraphPad Prism software
(GraphPad, La Jolla, CA, USA).
Results
Characterization of Fusion Proteins
The novel proteins luc2-iRFP720 and luc2-iRFP670 were
fused using the same 14 amino acid linker (Fig. 1A) used to
create the TurboLuc protein.20 In addition, Western blot anal-
ysis was performed to confirm the correct expression of the
fused proteins. luc2-iRFP720 and luc2-iRFP670 bands (*97
KDa) were localized above both luc2 (62KDa) and TurboLuc
(88KDa) bands (Fig. 1B). The new fusion proteins were effi-
ciently expressed in HEK-293 cells where colocalization of
luc2 and iRFP signals was observed using fluorescence micro-
scopy (Fig. 1C). Decreasing amounts of HEK-293 cells
expressing the fused proteins were then implanted subcuta-
neously in nude mice to check for sensitivity. Although luc2-
iRFP720 expressing cells gave low total fluorescent signals in
vivo, 1  104 cells were detectable while only 1  105 cells
weredetectable using luc2-iRFP670andTurboLuc (Fig. 2A,B),
thanks to an advantageous signal to noise ratio.
Proliferation of Transduced Human Mesenchymal
Stem Cells
Proliferation of hMSCs was evaluated after transduction for
2 consecutive passages (passage 3 to 5). Six days after
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transduction, cells observed under a microscope clearly
showed inhibited proliferation compared to control, non
transduced cells (Fig. 3A). Transduced cells had a doubling
time of 10 + 3 d significantly higher than non transduced
cells at that passage (7 + 1 d; P < 0.05). After 2 passages,
transduced cells showed a doubling time of 11+ 3 d com-
parable to non transduced cells that had an average doubling
time of 10+ 3 d (Fig. 3B).
Differentiation Ability of Transduced Human
Mesenchymal Stem Cells
Transduced cells were sorted for positive iRFP720 expres-
sion using FACS and subsequently expanded and passaged
for 3 times. At this time, hMSCs were stimulated to differ-
entiate. luc2-iRFP720 expressing hMSCs were able to dif-
ferentiate into adipogenic, osteogenic, and chondrogenic
cells as observed by the positive Oil Red O staining, Alizarin
Red staining, and toluidine staining, respectively (Fig. 4A).
The differentiation ability was further verified using specific
markers for the different cell lineages. In particular, cells
were positive for the adipogenic marker fatty acid–binding
protein (FABP4), chondrogenic marker aggrecan, and
osteogenic marker osteocalcin following a 14-d differentia-
tion protocol (Fig. 4B). No differences in differentiation
capabilities were observed when compared to non trans-
duced hMSCs at the same passage (data not shown).
We further characterized the formation of osteoblasts
when performing adipogenic differentiation measuring
ALP in medium for transduced and non transduced hMSCs.
Our results indicate that osteoblasts were not present during
adipogenic differentiation (Fig. 4C).
On the other hand, adipocytes were present during osteo-
genic differentiation (20% to 25% of the absorbance value at
540 nM) as reflected by the result of relative Oil Red O
accumulation using both transduced and non transduced
cells (Fig. 4D).
Sensitivity of In Vivo Fluorescence and Bioluminescence
Stem Cell Imaging
To evaluate the sensitivity of stem cell detection in vivo,
luc2-iRFP720 expressing hMSCs were implanted in the
mouse cortex. First, cell lines were characterized for their
emission properties in vitro. As expected, serial dilutions of
cells showed a linear correlation with both bioluminescence
Fig. 1. Generation of new fusion luciferase (luc2) reporters with near infrared fluorescence proteins. (A) Schematic drawing of the luc2
fusion with iRFP720 via a 14-aa linker. Photinus pyralis luc2 (PDB ID code 1LCI) and Chromophore-binding domain (CBD) of bacterial
phytochrome RpBphP2 (PDB ID code 4E04) were used. (B) Western blot results using an anti-luc2 primary antibody on human embryonic
kidney (HEK)-293 lysates used for transient expression of the proteins. The band in the first lane corresponds to luc2 protein (62 KDa), the
second to the TurboLuc protein (*88 KDa). The third and fourth lanes correspond to luc2-iRFP670 (abbreviated pLuc670) and luc2-
iRFP720 (abbreviated pLuc2720;*97 KDa). (C) Immunofluorescence for the analysis of colocalization of luc2 (green signal) and near infrared
proteins (red signal) in HEK-293 cells. Nuclei are stained with 40,6-diamidino-2-phenylindole (blue signal). luc2 was detected using an anti-luc2
antibody and Fluorescein isothiocyanate (FITC)-labeled secondary antibody. Near infrared proteins were detected using a 633-nM excitation
laser. Image on the left corresponds to cells expressing luc2-iRFP670 and image on the right corresponds to cells expressing luc2-iRFP720.
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and fluorescence signals. In vitro experiments using the ima-
ging conditions described in the Materials and Methods sec-
tion showed that luc2-iRFP720 expressing hMSCs emit an
average of 17 photons per second (ph/s) per cell and 0.019
relative light unit per cell of fluorescence (Fig. 5A, B). The
in vivo detection limit for BLI was 1  103 cells, while for
FLI, the in vivo detection limit was 1  105 luc2-iRFP720
expressing hMSCs (Fig. 5C, D).
Longitudinal Monitoring of Transduced Human
Mesenchymal Stem Cells in Mouse Brain
For longitudinal monitoring of luc2-iRFP720 expressing
hMSCs, 1  105 cells were transplanted into the cortex of
nude mice with initial high signals in order to maintain sen-
sitivity of detection over time. In our experiments, different
BLI protocols were evaluated, wherein different luciferin
substrates and doses were applied. D-Luc (943 mM/kg)
showed a significant higher signal with an average of 1 
107 ph/s when compared to CycLuc1 (25 mM/kg) and D-Luc
(25 mM/kg) in mouse brain (P  0.05; Fig. 6A, B). For that
reason, D-Luc (943 mM/kg) was utilized for the longitudinal
monitoring experiment, wherein BLI signals of
luc2-iRFP720 expressing hMSCs were measured in the
mouse brain. luc2-iRFP720 expressing hMSCs could still
be detected after a period of 7 wk in the mouse brain
(Fig. 7A) with an average of *1.3  107 ph/s and showed
no statistically significant differences in BLI or FLI signals
between the weeks (Fig. 7B, C).
Discussion
The main goal of this research was to develop a genetically
encoded reporter for multimodal optical imaging that would
allow for longitudinal monitoring of transplanted stem cells
with high sensitivity. We fused the codon-optimized firefly
luc2 and NIRFPs that were previously reported to be the
most sensitive reporters for deep tissue imaging.15,18 To fuse
the reporters, we opted for the 14-aa linker previously
employed in the generation of TurboLuc protein.20 The
novel fusion reporters luc2-iRFP670 and luc2-iRFP720 were
successfully expressed in HEK-293 cells. Moreover, subcu-
taneous transplantation of transiently transfected HEK-293
cells in nude mice revealed that iRFP720 has a substantially
lower background compared to iRFP670 and pTurboLuc,
making it superior to iRFP670 for imaging purposes as
shown already by Luker et al.18 Therefore, bone marrow–
derived hMSCs were transduced by a lentivirus expressing
luc2-iRFP720. However, before proceeding with in vivo
experiments, we evaluated whether transduction had an
Fig. 2. In vitro and in vivo characterization of different fusion proteins. (A) In vivo fluorescence imaging of different amounts of
human embryonic kidney-293 cells (blue circles) expressing TurboLuc (upper panel), luc2-iRFP670 (middle panel), and luc2-iRFP720 (lower
panel). Red circle indicates autofluorescent food signals from stomach. (B) Quantification of the signal given by 1  105 cells. TurboLuc
expressing cells show higher total signal. However, background signals are lower when using iRFP720 protein. Data are represented as
mean (SD) (n ¼ 3).
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effect on cell proliferation or whether the expression of the
novel fusion reporter would affect the differentiation cap-
abilities of hMSCs. Our results demonstrated that the trans-
duced hMSCs had a significantly lower doubling time
compared to non transduced control cells at passage 3, but
after consecutive passages, the doubling time was not sig-
nificantly different (passage 5). The effect of lentiviral trans-
duction using polybrene has been previously reported for
MSCs at first passage.22,23 In addition, transduced hMSCs
were able to differentiate into chondrocytes, adipocytes, and
osteocytes in accordance with previous reports, and no ill
effects were observed.24,25 This is especially important if
hMSCs are under investigation for regenerative purposes.
We further characterized the level of the expression of the
bioluminescent and fluorescent reporter and evaluated the
sensitivity of detection in vivo. The level of expression is
dependent on the choice of the promoter. The PGK promoter
is commonly used to express proteins in hMSCs.26 We are
aware that other constitutive promoters like elongation fac-
tor 1 would allow an even better expression, but no direct
comparisons have been reported in literature yet.27,28 Anal-
ysis and comparison of the BLI and FLI performances in
vivo were possible, since fusion of the reporters ensured
equimolar expression in cells. Our results showed that the
limit of detection using BLI is approximately 1  103
hMSCs in the brain cortex using a dose of 25 mM/kg of
D-Luc. Previous report showed that 3  103 stem cells were
visible using a dose of 943 mM/kg of D-Luc.29 Since trans-
duced stem cells emitted an average of 17 ph/s per cell in
vitro using our conditions, it is likely that cells with higher
Fig. 3. Effect of transduction on proliferation of human mesenchymal stem cells (hMSCs). (A) White-field microscopic images of hMSCs the
day before transduction (day 0, upper panel) and 6 d after transduction (lower panel) compared to non transduced cells used as controls.
(B) Graph reporting the calculated doubling time of control and transduced hMSCs. Transduced cells at passage 3 show a significantly higher
doubling time (*P < 0.05), but no significant differences in the 2 subsequent passages.
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photon fluxes would be able to lower the limit of detection in
vivo. On the contrary, the limit of detection using FLI is
around 1  105 cells. Although BLI has proven to be more
sensitive, our results support the use of iRFP720 fluorescent
protein for applications where higher amounts of cells are
transplanted. To date, the iRFP720 reporter has been used
Fig. 4. Histological staining and immunofluorescent staining of luc2-iRFP720 expressing human mesenchymal stem cells (hMSCs) in
determining differentiation capabilities. (A) Oil Red O staining showed the presence of fat deposition, toluidine blue staining showed the
presence of proteoglycans, and alizarin Red S showed the presence of calcific deposition after adipogenic, chondrogenic, and osteogenic
differentiation of luc2-iRFP720 expressing hMSCs, respectively. (B; left column) 40,6-diamidino-2-phenylindole (DAPI) staining showed cell
nuclei, (middle column) hMSC luc2-iRFP720 showed immunofluorescent staining of anti-mouse fatty acid binding protein 4 (anti-mFABP4),
anti-human aggrecan (anti-hAggrecan), and anti-human osteocalcin (anti-hOsteocalcin) after conditioned adipogenic, chondrogenic, and
osteogenic differentiation, respectively. (Right column) Merged images of DAPI and the specific antibody (n ¼ 3). (C) alkaline phosphatase
(ALP) activity measured in medium of luc2-iRFP720 expressing hMSCs, and non transduced hMSCs after 14 d of adipogenic or osteogenic
ALP activity during osteogenic differentiation are significantly higher (P < 0.01) than during adipogenic differentiation or undifferentiated
control cells. (D) Oil Red O absorbance values at 540 nM suggest that the level of adipocytes in different culturing conditions is not affected
by transduction, but it is significantly higher in adipogenic differentiation compared to osteogenic differentiation or undifferentiated cells
(*P < 0.05 and **P < 0.01).
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Fig. 5. Serial dilutions of luc2-iRFP720 expressing human mesenchymal stem cells (hMSCs) measured for bioluminescence and fluorescence
intensity. (A) Bioluminescence imaging (BLI) was measured for the serial dilution of of luc2-iRFP720 expressing hMSCs (0, 3.125, 6.250,
12.500, 25.000, and 50.000 cells; r2 ¼ 0.9921). Data are represented as mean (SD) (n ¼ 3). (B) fluorescence imaging (FLI) was measured for
the serial dilution (0, 3.125, 6.250, 12.500, 25.000, 50.000, and 100.000 cells) at 700 nm (r2 ¼ 0.9980) using the Odyssey scanner. Data are
represented as mean (SD) (n¼ 6). (C) BLI of decreased amount of cells (1  103, 1  104, 1 105, and 1  106). Images were taken 20 min
after injection of D-luciferin (25 mM/kg). (D) FLI of decreased amounts of cells (1 103, 1 104, 1 105, and 1 106) when injected into the
mouse brain using Pearl Imager with 700 nm settings.
Fig. 6. Bioluminescence imaging (BLI) signal in vivo of D-luciferin (D-Luc; 25 mM/kg), CycLuc1 (25 mM/kg), and D-Luc (943 mM/kg) in the
mouse brain. (A; top) Injected with D-Luc (25 mM/kg), (middle) injected with CycLuc1 (25 mM/kg), and (bottom) injected with D-Luc (943
mM/kg) in mouse brain. (B) The graph showed that D-Luc (943 mM/kg) gives significantly higher BLI signals (*1  107) than D-Luc and
CycLuc1 (25 mM/kg). Data are represented as mean (SD) (n ¼ 3; *P  0.05).
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only for monitoring tumor progression using FLI.30 In addi-
tion, iRFP720 has shown potential for photoacoustic ima-
ging of tumor progression.31 However, in both applications,
millions of cells need to be transplanted. To achieve further
sensitivity using BLI, we explored the use of different D-Luc
substrates and doses after i.p. injection. In fact, it is known
that D-Luc can pass the blood–brain barrier (BBB), but the
concentration of D-Luc in the brain following i.p. injection
of a dose of 422 mM/kg (generally considered as a standard)
is far from being saturating and it can be further increased
and well tolerated.32 Aswendt et al., for example, reported
superior performances for imaging transplanted stem cells
with a D-Luc dose of 943 mM/kg.29 On the other hand, a dose
of 25 mM/kg of CycLuc1 was reported to enhance imaging
sensitivity of lentivirally transduced endogenous cells in the
mouse brain when compared to the standard dose of D-Luc
of 422 mM/kg.16 Considering these recent reports, we aimed
to compare a dose of 25 mM/kg of CycLuc1 to a dose of 25
mM/kg and 943 mM/kg of D-Luc. Using a dose of 943 mM/kg
of CycLuc1 is not possible due to the limited solubility of the
compound (maximum solubility 100 mg/mL in dimethyl
sulfoxide [DMSO] that allows injecting a maximum of 160
mM/kg i.p. in 5% DMSO).16 Importantly, signals were com-
pared when emissions peaked after substrate injection. In
particular, experiments were carried out 1 wk after cell trans-
plantation when the BBB was restored to take into account
the different influx of D-Luc and CycLuc1 when the BBB
was breached. Our results demonstrated that using a higher
dose of D-Luc was able to generate brighter signals in brain
cortex than 25 mM/kg of CycLuc.16 Following this protocol,
initially transplanted 1  105 hMSCs could be detected in
the cortex of the mouse brain for 7 wk without any substan-
tial drop in BLI signals, analogous to the findings of Tenn-
staedt et al., wherein 3  105 human neuronal stem cells
could be detected in the cortices of mice for several weeks.33
Remarkably, the generated photon flux (ph/s) was about 107
ph/s, a flux higher than previously reported for imaging
transplanted stem cells at this depth.11,15,30,33–35
In addition, cells could be detected using FLI of the
iRFP720 protein. To the best of our knowledge, there are
no other reports where less than 105 hMSCs could be
detected with adequate sensitivity and resolution in the brain
cortex for several weeks using optical imaging. In conclu-
sion, the 3 pending questions have found an answer. The
Fig. 7. (A) Longitudinal monitoring of luc2-iRFP720 expressing human mesenchymal stem cells when injected in the mouse brain followed
for 1, 3, 5, and 7 wk. (B) No significant differences in bioluminescence imaging of fluorescence imaging signal were observed between the
weeks. Data are represented as mean (SD) (n ¼ 4; **P < 0.01 and *P < 0.05).
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novel fusion reporter showed that BLI allows for more sen-
sitive imaging in the brain than iRFP720. The latter remains
a good option for imaging an amount of cells higher than
1  105. A concentration of D-Luc of 943 mM/kg allows for
the efficient tracking of transplanted stem cells in the mouse
brain using optical imaging for at least 7 wk.
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